Brace for an end-of-year boost to drug approvals
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
US drug pricing reform happens at last
As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
No plain sailing for Novartis’s PD-1 plan
Getting the Swiss firm’s Beigene-derived anti-PD-1 MAb across the US finish line is proving harder than expected.
Sarepta loses its Momentum
A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.
